{"entity":{"id":"pairidex","kind":"company","name":"Pairidex","aka":[],"tldr":"Pairidex makes a personalised blood test that tracks the gene fusion driving a person's leukaemia, so their doctors can see how well treatment is working and spot a return of the disease early.","summary":"Pairidex is a St. Louis company developing FusionMRD, a personalised droplet digital PCR assay that detects the gene fusion driving an individual patient's blood cancer, for monitoring treatment response and long-term surveillance of measurable residual disease. It starts with fusion-driven acute myeloid leukaemia and runs the test in a CLIA-certified, CAP-accredited laboratory. Andrew Young is founder and chief scientific officer. In February 2026 it announced a pre-seed lead investment from BioGenerator Ventures, and in July 2026 it closed an oversubscribed seed round bringing in USD 4.89 million to support the commercial launch of FusionMRD; the company described the seed investor only as a large, publicly held strategic company.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.pairidex.com/"},{"label":"Company news and funding releases","url":"https://www.pairidex.com/news"}],"tags":[],"related":[],"cancers":["aml"],"sections":["diagnostics"],"technologies":["mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated; the St. Louis Business Journal reported in February 2026 that the company had established operations just over a year earlier. The funding source is the company's news page, which links the EIN Presswire releases. Analytical performance claims were not checked against a publication."],"hq":"St. Louis, MO","country":"US","companyType":"diagnostics","website":"https://www.pairidex.com/","stage":"startup","investors":[],"funding":[{"round":"Pre-seed","year":2026,"source":"https://www.pairidex.com/news","note":"Led by BioGenerator Ventures; amount not disclosed"},{"round":"Seed","year":2026,"amountUsd":4890000,"source":"https://www.pairidex.com/news","note":"Oversubscribed; investor not named"}]},"route":"/companies/pairidex/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}]}}